Mitchell S von Itzstein

13PUBLICATIONS
41CO-AUTHORS
Molecular targetsPredictive and prognostic markersAgricultural molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)Autoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 18, 2026
Predictive Biomarkers for Immune Checkpoint Inhibitor Efficacy: Challenges, Innovations, and a Pathway to Precision Medicine in the Era of Cancer Immunotherapy.

|Jun 13, 2026
Deciphering small sequence differences in T cell receptor-antigen pairing.

|Mar 11, 2026
A new therapeutic approach to KRAS mutant non-small cell lung cancer: the emerging role of exportin 1 inhibition.

Mitchell S von Itzstein, David E Gerber

|Sep 26, 2025
Nipah and Hendra Viruses Use an Adjustable Latch in Receptor Engagement.

Mitchell S von Itzstein, Moritz Winger, Alpeshkumar K Malde

|Dec 09, 2024
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer.

Mitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell

|Mar 10, 2022
Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy.

Mitchell S von Itzstein, Amrit S Gonugunta, Thomas Sheffield

Pageof 3

Frequent Collaborators

6 joint publications

David E Gerber

2 joint publications

John D Minna

1 joint publications

Elda Railey

1 joint publications

Benjamin J Drapkin